Reata Pharmaceuticals

General Information

We are a clinical stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases. Our lead product candidates, bardoxolone methyl and RTA 408, are members of a class of small molecules called antioxidant inflammation modulators, or AIMs. Bardoxolone methyl is in Phase 2 clinical development for the treatment of pulmonary arterial hypertension, or PAH, and pulmonary hypertension due to interstitial lung disease, or PH-ILD, each of which are subsets of pulmonary hypertension, or PH. Initial data for PAH patients in our Phase 2 trial have been presented publicly at the CHEST meeting in October 2015. In addition, we have completed an interaction with the U.S. Food and Drug Administration, or FDA, on this initial data, and the FDA has concurred with our plan to initiate a Phase 3 trial in patients with PAH associated with connective tissue disease, or CTD-PAH.


Employees: 64
Founded: 2002
Contact Information
Address 2801 Gateway Drive, Suite 150, Irving, TX 75063, US
Phone Number (972) 865-2219
Web Address
View Prospectus: Reata Pharmaceuticals
Financial Information
Market Cap $300.0mil
Revenues $52.4 mil (last 12 months)
Net Income $-2.4 mil (last 12 months)
IPO Profile
Symbol RETA
Exchange NASDAQ
Shares (millions): 5.5
Price range $11.00 - $11.00
Est. $ Volume $60.5 mil
Manager / Joint Managers Citigroup/ Cowen and Company/ Piper Jaffray
CO-Managers -
Expected To Trade: 5/26/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change